#1 Clinical Trials Search in Europe

Itacitinib

Itacitinib is an experimental drug being studied in clinical trials for its potential to treat a variety of conditions, including graft-versus-host disease (GVHD), bronchiolitis obliterans syndrome (BOS), rheumatoid arthritis, and certain blood cancers. This article summarizes the current research on Itacitinib, its mechanisms of action, and its potential benefits for patients with these challenging medical conditions.

Table of Contents

What is Itacitinib?

Itacitinib is an experimental drug that is being studied for its potential to treat various medical conditions. It is also known by other names such as INCB039110 or INCB039110 adipate[9][7]. Itacitinib belongs to a class of medications called JAK inhibitors, specifically targeting an enzyme called JAK1 (Janus kinase 1)[1].

How Itacitinib Works

Itacitinib works by inhibiting the activity of JAK1, an enzyme involved in the body’s immune and inflammatory responses. By blocking JAK1, itacitinib can help reduce inflammation and modulate the immune system. This mechanism of action makes it potentially useful in treating various conditions characterized by excessive inflammation or immune system dysfunction[1].

Conditions Treated with Itacitinib

Itacitinib is being studied for its potential to treat several medical conditions, including:

  • Graft-versus-host disease (GVHD): A complication that can occur after bone marrow or stem cell transplants, where the donated cells attack the recipient’s body[6][7].
  • Myelofibrosis: A rare type of blood cancer that affects bone marrow function[10].
  • Rheumatoid arthritis: An autoimmune disease causing inflammation in joints[9].
  • Bronchiolitis obliterans syndrome (BOS): A lung condition that can occur after lung transplantation[4].
  • Hemophagocytic lymphohistiocytosis (HLH): A rare but severe condition where the immune system becomes overactive[1].
  • Advanced solid tumors: Various types of cancers that form solid masses[8].

Clinical Trials and Research

Itacitinib is currently being studied in several clinical trials to evaluate its safety and effectiveness in treating different conditions:

  • A study is exploring its use in treating non-severe hemophagocytic lymphohistiocytosis (HLH)[1].
  • Another trial is investigating its potential in preventing and treating cytokine release syndrome in older patients undergoing stem cell transplantation[5].
  • Researchers are also studying itacitinib for the treatment of bronchiolitis obliterans syndrome following lung transplantation[4].
  • A trial is evaluating its effectiveness in treating rheumatoid arthritis[9].
  • Studies are ongoing to assess its potential in treating various types of graft-versus-host disease[6][7].

How Itacitinib is Administered

Itacitinib is typically administered orally in the form of tablets. The dosage and frequency of administration can vary depending on the condition being treated and the specific clinical trial protocol. Some common dosing regimens include:

  • Once daily dosing, ranging from 100 mg to 600 mg[4][10].
  • Twice daily dosing, with doses ranging from 100 mg to 400 mg[9].

The duration of treatment can also vary, ranging from a few weeks to several months, depending on the study and the patient’s response to the medication[7].

Potential Side Effects

As with any medication, itacitinib may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some trials are specifically designed to monitor for:

  • Changes in blood cell counts
  • Liver function abnormalities
  • Increased risk of infections
  • Other general adverse events[2]

It’s important to note that as an experimental drug, the safety profile of itacitinib is still being established. Patients participating in clinical trials are closely monitored for any adverse effects[2].

Aspect Details
Drug Name Itacitinib (also known as INCB039110)
Mechanism of Action Selective JAK1 inhibitor
Administration Oral tablets, typically once or twice daily
Conditions Studied Graft-versus-host disease (GVHD), Bronchiolitis obliterans syndrome (BOS), Rheumatoid arthritis, Myelofibrosis, Leukemia
Potential Benefits Reduction of inflammation, suppression of overactive immune responses, prevention of complications in transplant procedures
Clinical Trial Phases Phase 1, Phase 2, and some Phase 1/2 combination studies
Safety Monitoring Ongoing evaluation of adverse events, tolerability, and long-term effects
Combination Therapies Being studied in combination with other drugs for potential synergistic effects

FAQ

  • What is Itacitinib? Itacitinib is an experimental drug that works by inhibiting JAK1, an enzyme involved in inflammation and immune responses. It is being studied for its potential to treat various conditions, including graft-versus-host disease, bronchiolitis obliterans syndrome, and rheumatoid arthritis.
  • What conditions is Itacitinib being tested for in clinical trials? Itacitinib is being tested in clinical trials for several conditions, including graft-versus-host disease (GVHD), bronchiolitis obliterans syndrome (BOS) following lung transplantation, rheumatoid arthritis, and certain blood cancers such as myelofibrosis and leukemia.
  • How is Itacitinib administered? Itacitinib is typically administered orally in tablet form. The dosage and frequency can vary depending on the specific clinical trial and condition being treated, but it is often given once or twice daily.
  • What are the potential benefits of Itacitinib? Potential benefits of Itacitinib include reducing inflammation, suppressing overactive immune responses, and improving symptoms in conditions like GVHD and BOS. It may also help prevent complications such as cytokine release syndrome in certain transplant procedures.
  • Are there any known side effects of Itacitinib? As with any experimental drug, the full range of side effects is still being studied. Clinical trials are designed to monitor for adverse events and evaluate the safety and tolerability of Itacitinib. Common side effects observed in trials may include changes in blood cell counts, liver enzyme elevations, and infections.

Ongoing Clinical Trials on Itacitinib

  • Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Itacitinib for Adults with Diffuse Systemic Sclerosis

    Not recruiting

    1
    Investigated drugs:
    France

  • Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Greece Italy Spain

Glossary

  • JAK1: JAK1 (Janus Kinase 1) is an enzyme involved in signaling pathways that regulate inflammation and immune responses in the body. Itacitinib works by selectively inhibiting JAK1.
  • Graft-versus-host disease (GVHD): A condition that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient's body, causing inflammation and damage to various organs.
  • Bronchiolitis obliterans syndrome (BOS): A form of chronic lung allograft dysfunction that can occur after lung transplantation, characterized by inflammation and scarring of the small airways (bronchioles).
  • Cytokine release syndrome (CRS): A systemic inflammatory response that can occur as a complication of certain immunotherapies or transplant procedures, characterized by high fever, low blood pressure, and organ dysfunction.
  • Rheumatoid arthritis: A chronic autoimmune disease that causes inflammation, pain, and stiffness in the joints, potentially leading to joint damage and disability.
  • Myelofibrosis: A rare blood cancer that affects the bone marrow, leading to scarring and impaired blood cell production.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.

References

  1. https://clinicaltrials.eu/trial/study-on-itacitinib-for-treating-non-severe-hemophagocytic-lymphohistiocytosis-in-adults/
  2. https://clinicaltrials.gov/study/NCT04640025
  3. https://clinicaltrials.gov/study/NCT04239989
  4. https://clinicaltrials.gov/study/NCT03978637
  5. https://clinicaltrials.gov/study/NCT05823571
  6. https://clinicaltrials.gov/study/NCT04200365
  7. https://clinicaltrials.gov/study/NCT03846479
  8. https://clinicaltrials.gov/study/NCT02559492
  9. https://clinicaltrials.gov/study/NCT01626573
  10. https://clinicaltrials.gov/study/NCT01633372